5,6,6a,7,8,12b-hexahydro-benzo[a]phenanthridine | 94133-12-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5,6,6a,7,8,12b-hexahydro-benzo[a]phenanthridine
• 英文别名: 5,6,6a,7,8,12b-Hexahydrobenzo[a]phenanthridine；5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine
• CAS: 94133-12-7
• 化学式: C₁₇H₁₇N
• 分子量: 235.329
• InChiKey: YROUKTGODHHOAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Co-administration of dopamine-receptor binding compounds
  申请人：Fernandes B. Prabhavathi

  公开号：US20070155720A1

  公开（公告）日：2007-07-05

  Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D 1 receptor agonist, and administering to the patient an effective amount of a dopamine D 2 receptor antagonist. Pharmaceutical compositions comprising a dopamine D 1 receptor agonist and a dopamine D 2 receptor antagonist are also described. The D 1 dopamine receptor agonist and the D 2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

  描述了治疗患有神经、精神和精神障碍的患者的方法，包括向患者施用部分和/或全多巴胺D1受体激动剂的有效量，并向患者施用多巴胺D2受体拮抗剂的有效量。还描述了包含多巴胺D1受体激动剂和多巴胺D2受体拮抗剂的药物组合物。D1多巴胺受体激动剂和D2多巴胺受体拮抗剂可以以相同或不同的组合或组合物形式向患者施用。
• Co-Administration of Dopamine-Receptor Binding Compounds
  申请人：Fernandes Prabhavathi B.

  公开号：US20100041690A1

  公开（公告）日：2010-02-18

  Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D 1 receptor agonist, and administering to the patient an effective amount of a dopamine D 2 receptor antagonist, Pharmaceutical compositions comprising a dopamine D 1 receptor agonist and a dopamine D 2 receptor antagonist are also described. The D 1 dopamine receptor agonist and the D 2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

  描述了治疗神经、精神和精神障碍患者的方法，包括向患者施用部分和/或完全的多巴胺D1受体激动剂的有效剂量，并向患者施用多巴胺D2受体拮抗剂的有效剂量。还描述了包含多巴胺D1受体激动剂和多巴胺D2受体拮抗剂的药物组合物。D1多巴胺受体激动剂和D2多巴胺受体拮抗剂可以在同一组合物或不同组合物中向患者施用。
• DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION
  申请人：Mailman Richard B.

  公开号：US20110190332A1

  公开（公告）日：2011-08-04

  Trans-hexahydrobenzoaphenanthridines of the formula (I) wherein X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined herein, are disclosed. Pharmaceutical formulations including such compounds, and methods of using such compounds for treating a patient suffering from dopamine-related dysfunction of the central or peripheral nervous system are also disclosed.

  本文披露了式(I)的跨六氢苯并苯并哌啶，其中X、Y、R1、R2、R3、R4、R5、R6和R7如本文所定义。还披露了包括这些化合物的制药配方，以及使用这些化合物治疗中枢或外周神经系统多巴胺相关功能障碍的患者的方法。
• EP0644877A4
  申请人：——

  公开号：EP0644877A4

  公开（公告）日：1995-02-03
• SUBSTITUTED-HEXAHYDROBENZO A]PHENANTHRIDINES
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：EP0644877A1

  公开（公告）日：1995-03-29